Britain and America have hammered out a landmark trade agreement that will guarantee zero import taxes on British pharmaceutical shipments entering the American market.
The Terms of the Deal
As part of the deal, the UK has pledged to increase spending on drugs through the NHS. This pledge secures that import taxes on these vital goods will be held at nothing for a timeframe of 36 months.
This agreement follows earlier threats to hike import taxes on branded pharmaceutical products, with increases mentioned as high as double the cost.
"This agreement with the Britain strengthens the worldwide climate for new treatments and brings long-overdue fairness to U.S.–U.K. drug exports," an announcement noted.
Economic Significance
Pharmaceuticals constitute one of the Britain's most significant exports to the US, which is easily the largest destination for leading companies like GSK and AstraZeneca.
Export figures reveal that in the year leading up to the third quarter, the UK sold medicines totaling £11.1bn to the US. This figure accounted for nearly one-fifth of total UK exports in that timeframe.
"This deal secures work, increases investment and facilitates the UK to become a international leader for medical research," the Business and Trade Secretary stated.
Detailed NHS Changes
The agreement includes several notable pledges from the United Kingdom:
- Price Threshold Increase: The UK will increase the cost ceiling at which it considers new treatments to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a goal to increase overall NHS spending on treatments from 0.3 percent of GDP to 0.6% over the next decade.
- Rebate Cap: The sum drug companies must refund to the NHS to control costs will be restricted at 15%. Previously, rebates were more than 20%.
Broader Context
The deal follows a protracted tension between the sector and the ministers over drug pricing and approval rates.
This friction were intensified by arguments that US consumers were charged a premium for the equivalent treatments than people in the other developed nations.
Recently, several significant drug company projects in the UK have been paused or abandoned, while multi-billion-dollar investments have been directed toward US facilities.
A senior figure acknowledged that the NHS must spend more on drugs, noting that its expenditure on drugs had declined as a share of its overall budget over the past decade.
